Literatur
Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W et al (2015) Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33(34):4032–4038. https://doi.org/10.1200/JCO.2015.63.2497
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 8(4):428–443. https://doi.org/10.1158/2159-8290.CD-17-1226
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R et al (2015) Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 33(34):4023–4031. https://doi.org/10.1200/JCO.2015.63.2471
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Pamuk, T. Zander, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Pamuk, A., Zander, T., Alakus, H. et al. Therapie des BRAF-V600E-mutierten kolorektalen Karzinoms im metastasierten Stadium. Onkologe 26, 292–294 (2020). https://doi.org/10.1007/s00761-019-00703-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-019-00703-7